Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells
Thyroid carcinoma
multikinase inhibitor
radioiodine-refractory thyroid cancer
redifferentiation
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
25
11
2020
revised:
08
12
2020
accepted:
09
12
2020
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells. Four established cell lines and three patient's cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured. The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed. Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
We evaluated the potential of the kinase inhibitors sorafenib, lenvatinib and selumetinib on increasing the uptake of technetium-99m into thyroid cancer cells.
MATERIALS AND METHODS
METHODS
Four established cell lines and three patient's cell cultures were treated with 0.1, 1 and 5 μM of sorafenib, lenvatinib and selumetinib for 72 hours. After incubation with 1 MBq of technetium-99m, the radioactivity uptake was measured.
RESULTS
RESULTS
The experiments showed heterogeneous results. Maximum technetium-99m uptake increases of 312% (sorafenib), 326% (lenvatinib) and 759% (selumetinib) were obtained using the highest applied concentrations. In some tests, an uptake reduction or no effect was observed.
CONCLUSION
CONCLUSIONS
Kinase inhibitors have a positive effect on technetium-99m uptake. Due to study limitations, a redifferentiating effect of the drugs could not be definitely proven. Unspecific cytotoxicity might have a confounding effect.
Identifiants
pubmed: 33622865
pii: 35/2/721
doi: 10.21873/invivo.12313
pmc: PMC8045076
doi:
Substances chimiques
Technetium
7440-26-8
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
721-729Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Eur J Endocrinol. 2015 May;172(5):R215-25
pubmed: 25572389
Eur J Endocrinol. 2009 Dec;161(6):923-31
pubmed: 19773371
J Clin Oncol. 2012 Jan 10;30(2):134-41
pubmed: 22025146
Drug Des Devel Ther. 2016 Mar 11;10:1119-31
pubmed: 27042004
Endocr Rev. 2019 Dec 1;40(6):1573-1604
pubmed: 31322645
Eur Thyroid J. 2019 Oct;8(5):227-245
pubmed: 31768334
Mod Pathol. 2011 Apr;24 Suppl 2:S44-52
pubmed: 21455200
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
J Nucl Med. 2019 Jan;60(1):9-15
pubmed: 30190306
Endocr Relat Cancer. 2020 May;27(5):R113-R132
pubmed: 32191916
Clin Cancer Res. 2012 Apr 1;18(7):2056-65
pubmed: 22241789
Onco Targets Ther. 2016 Oct 20;9:6467-6477
pubmed: 27799794
Gland Surg. 2020 Jan;9(Suppl 1):S28-S42
pubmed: 32055496
Eur J Cancer. 2018 Mar;92:40-47
pubmed: 29413688
Int J Surg Case Rep. 2016;25:174-8
pubmed: 27379749
Thyroid. 2013 May;23(5):600-4
pubmed: 23113752
BMC Cancer. 2015 Mar 26;15:184
pubmed: 25879531
Indian J Endocrinol Metab. 2019 Jul-Aug;23(4):480-485
pubmed: 31741910
Future Oncol. 2019 Mar;15(7):717-726
pubmed: 30638399
Lancet. 2014 Jul 26;384(9940):319-28
pubmed: 24768112
Int J Mol Sci. 2018 Jul 17;19(7):
pubmed: 30018229
N Engl J Med. 2013 Feb 14;368(7):623-32
pubmed: 23406027